



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Saxon et al. Docket No.: 39754-0672A
Serial No.: 09/847,208 Group Art Unit: 1644
Filing Date: May 1, 2001 Examiner: Phuong N. Huynh
For: **FUSION MOLECULES AND TREATMENT OF IgE-MEDIATED
ALLERGIC DISEASES**

Express Mail No.: EL 992 479 704 US
Mailing Date: December 29, 2003

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, can be found attached, according to 35 U.S.C. 120, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

01/06/2004 ZJUHR1 00000106 081641 09847208
02 FC:1806 180.00 DA

- ☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)
-- OR --
- ☐ (2) It is being filed within 3 months of entry of a national stage
-- OR --
- ☐ (3) It is being filed before the mail date of the first Office Action on the merits
-- OR --
- ☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

☒ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:

☐ a certification as specified in §1.97(e) is provided below; or

☒ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☐ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:

A. a certification as specified in §1.97(e) is completed below; and

B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and

C. a fee of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.

☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of \$180.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39754-0672 A).

Respectfully submitted,

Dated: Dec 29, 2003

By: Leslie A. Mooi
Leslie A. Mooi, Reg. No. 37,047

HELLER EHRMAN WHITE & McAULIFFE LLP
Customer No. 25213
275 Middlefield Road
Menlo Park, CA 94025-3506
(650) 324-7000



INFORMATION DISCLOSURE CITATION PTO-1449			ATTY. DOCKET NO. 39754-0672 A		SERIAL NO. 09/847,208		
			APPLICANT Saxon et al.				
			FILING DATE 05/01/2001		GROUP 1644		
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
FOREIGN PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Kepley et al., "FcεRI-FcγRII Coaggregation inhibits IL-16 production from human langerhans-like dendritic cells", <i>Clinical Immunology</i> , 108: 89-94 (2003)						
	Jeff Miner, "Experimental Therapy Stops Allergic Reactions in Mice", <i>NIAID News</i> , 1-2 (May 2002)						
	Shields et al., "High Resolution Mapping of the Binding Site on Human IgG1 for FcγR1, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR", <i>The Journal of Biological Chemistry</i> , 276:(9) 6591-6604 (2001)						
	Zhu et al., "A novel human immunoglobulin Fcγ-Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation", <i>Nature Medicine</i> , 8:(5) 518-521 (May 2002)						
EXAMINER			DATE CONSIDERED				